Compare PulteGroup, Inc. (PHM) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PulteGroup, Inc. vs Repligen Corporation Common Stock — how do they compare? PulteGroup, Inc. trades at $110.09 (market cap $21.25B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: PulteGroup, Inc. is the larger of the two by market cap, and PulteGroup, Inc. pays a 0.93% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold PulteGroup, Inc. for 91 Days and Repligen Corporation Common Stock for 0 Days on average.
| PHM | RGEN | |
|---|---|---|
Market Cap | $21.25B | $11.14B |
Volume | 1,784,813 | 1,259,263 |
Sector | Consumer Cyclical | Health |
52-Week High | $142.56 | $194.57 |
52-Week Low | $109.35 | $102.87 |
Typical Hold Time | 91 Days | 0 Days |
Enterprise Value | $21.67B | $11.02B |
Dividend Yield | 0.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PulteGroup (PHM) trades at $109.35, down 1.61% amid broader housing sector pressure from rising mortgage rates. The stock shows bearish technical signals with recent earnings misses in Q4 2025 and Q1 2026, though it beat expectations in Q2 2026. Fundamentally, the company maintains solid profitability with 11.62% net margin and attractive valuation at 11.4 P/E. Analyst consensus remains mixed with 45% buy ratings but a $139.64 price target suggesting 28% upside potential from current levels.
PHM presents a value opportunity with strong cash flow generation and dividend yield, though near-term headwinds from rising interest rates and housing affordability concerns create volatility. The stock's current discount to analyst targets and reasonable valuation metrics support long-term potential, but investors should monitor Q3 2026 earnings on October 22 for confirmation of business resilience.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
